Advertisement
Table 4 Clinical risk factors for SSEs in two groups
| Denosumab | ZA | |||
|---|---|---|---|---|
| Risk factors | HR(95%CI) | P –value | HR(95%CI) | P - value |
| Age (y) | 0.003* | 0.001* | ||
| ≤60 | 1 | 1 | ||
| > 60 | 3.13(1.02–1.68) | 4.72(2.36–7.17) | ||
| Menopause age(y) | 0.440 | 0.247 | ||
| ≤50 | 5.04(0.03–22.12) | 5.04(0.03–22.12) | ||
| > 50 | 1 | 1 | ||
| PHF | 0.002* | 0.005* | ||
| no | 1 | 1 | ||
| yes | 21.34(5.23–49.12) | 36.75(2.39–74.32) | ||
| FHF | 0.037* | 0.041* | ||
| no | 1 | 1 | ||
| yes | 6.79(1.10–11.65) | 8.86(1.43–38.15) | ||
| BMI(kg/m2) | 0.793 | 0.219 | ||
| ≤19 | 3.76(0.66–31.32) | 5.36(0.19–44.61) | ||
| > 19 | 1 | 1 | ||
